ATE152175T1 - Nukleotidsequenz, die für ein aussenmembran- protein von neisseria meningitidis kodiert und verwendung dieses proteins zur herstellung von impfstoffen - Google Patents

Nukleotidsequenz, die für ein aussenmembran- protein von neisseria meningitidis kodiert und verwendung dieses proteins zur herstellung von impfstoffen

Info

Publication number
ATE152175T1
ATE152175T1 AT91202291T AT91202291T ATE152175T1 AT E152175 T1 ATE152175 T1 AT E152175T1 AT 91202291 T AT91202291 T AT 91202291T AT 91202291 T AT91202291 T AT 91202291T AT E152175 T1 ATE152175 T1 AT E152175T1
Authority
AT
Austria
Prior art keywords
protein
nucleotide sequence
outer membrane
sequence coding
neisseria meningitidis
Prior art date
Application number
AT91202291T
Other languages
English (en)
Inventor
Ricardo Silva Rodriguez
Sosa Manuel Selman Houssein
Gerardo Guillen Nieto
Martinez Luis S Herrera
Maso Julio Raul Fernandez
Perez Lidia Ines Novoa
Juan Morales Grillo
Cordova Vivian Morera
Blanco Sonia Gonzalez
Beatriz Tamargo Santos
Calixto Reparto
Valle Rosales Jesus August Del
Alegre Vista
Evelin Caballero Menendez
Acosta Anabel Alvarez
Rodriguez Edelgis Couzeau
Leon Silian Cruz
Lasa Alexis Musacchio
Original Assignee
Cigb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cigb filed Critical Cigb
Application granted granted Critical
Publication of ATE152175T1 publication Critical patent/ATE152175T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01004—Dihydrolipoyl dehydrogenase (1.8.1.4), i.e. lipoamide-dehydrogenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT91202291T 1990-09-07 1991-09-06 Nukleotidsequenz, die für ein aussenmembran- protein von neisseria meningitidis kodiert und verwendung dieses proteins zur herstellung von impfstoffen ATE152175T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU90145A CU22302A1 (es) 1990-09-07 1990-09-07 Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales

Publications (1)

Publication Number Publication Date
ATE152175T1 true ATE152175T1 (de) 1997-05-15

Family

ID=5459451

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91202291T ATE152175T1 (de) 1990-09-07 1991-09-06 Nukleotidsequenz, die für ein aussenmembran- protein von neisseria meningitidis kodiert und verwendung dieses proteins zur herstellung von impfstoffen

Country Status (15)

Country Link
US (1) US5286484A (de)
EP (1) EP0474313B1 (de)
JP (1) JP3253327B2 (de)
AR (1) AR245778A1 (de)
AT (1) ATE152175T1 (de)
AU (1) AU657487B2 (de)
CA (1) CA2050749C (de)
CU (1) CU22302A1 (de)
DE (1) DE69125769T2 (de)
ES (1) ES2103295T3 (de)
FI (1) FI103511B (de)
GR (1) GR3024127T3 (de)
IL (1) IL99401A (de)
NO (1) NO913524D0 (de)
RU (1) RU2132383C1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
WO1996000233A1 (en) * 1994-06-24 1996-01-04 Children's Hospital And Medical Center Escherichia coli o157:h7 epithelial adhesin
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6287574B1 (en) 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
WO1998009990A1 (en) * 1996-09-04 1998-03-12 Takara Shuzo Co., Ltd. Fungal antigens and process for producing the same
EP1047784B2 (de) * 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Antigene aus neisseria meningitidis
EP1073748A2 (de) * 1998-04-29 2001-02-07 American Cyanamid Company Impstoffe die rekombinantes pilin gegen neisseria gonorrhoeae oder neisseria meningitidis enthalten
EP2261338A3 (de) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
US6693186B2 (en) * 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6756493B1 (en) * 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
BR9914374A (pt) * 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
US6610306B2 (en) 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
ES2310776T3 (es) * 1998-10-22 2009-01-16 The University Of Montana Composiciones de vacuna que comprenden proteinas omp de neisseria gonorrhoeae y de neisseria meningitidis.
WO2000023595A1 (en) * 1998-10-22 2000-04-27 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
EP1939215A1 (de) 1998-10-22 2008-07-02 The University of Montana Omp85-Proteien von Neisseria Gonorrhoeae und Neisseria Meningitidis, Zusammensetzungen damit und ihre Verwendungsverfahren
NZ521531A (en) 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
EP1274732A1 (de) * 2000-04-20 2003-01-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Sekretorisches tyrosine phosphatase aus mykobakterium
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US20060057160A1 (en) * 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE031886T2 (en) * 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
AU2003281909A1 (en) * 2002-11-14 2004-06-03 Instituto Finlay. Centro De Investigacion-Produccion De Vacunas Y Sueros. Method of obtaining conjugate vaccines and vaccine compositions containing same
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
EP1613261A4 (de) 2003-04-09 2011-01-26 Novo Nordisk As Intrazelluläre bildung von peptidkonjugaten
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
NZ550533A (en) * 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в

Also Published As

Publication number Publication date
CA2050749A1 (en) 1992-03-08
RU2132383C1 (ru) 1999-06-27
CA2050749C (en) 2002-07-02
FI103511B1 (fi) 1999-07-15
GR3024127T3 (en) 1997-10-31
IL99401A0 (en) 1992-08-18
FI914129A7 (fi) 1992-03-08
JPH06169779A (ja) 1994-06-21
FI914129A0 (fi) 1991-09-03
AU8368391A (en) 1992-03-12
AR245778A1 (es) 1994-02-28
IL99401A (en) 2003-12-10
CU22302A1 (es) 1995-01-31
EP0474313B1 (de) 1997-04-23
FI103511B (fi) 1999-07-15
JP3253327B2 (ja) 2002-02-04
ES2103295T3 (es) 1997-09-16
AU657487B2 (en) 1995-03-16
DE69125769T2 (de) 1997-11-27
US5286484A (en) 1994-02-15
NO913524D0 (no) 1991-09-06
EP0474313A3 (en) 1993-02-24
EP0474313A2 (de) 1992-03-11
DE69125769D1 (de) 1997-05-28

Similar Documents

Publication Publication Date Title
ATE152175T1 (de) Nukleotidsequenz, die für ein aussenmembran- protein von neisseria meningitidis kodiert und verwendung dieses proteins zur herstellung von impfstoffen
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE3382190D1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
ATE176924T1 (de) Verfahren zur herstellung von menschlicher dnase
DE3587422D1 (de) Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
DE68925083D1 (de) Rekombinante DNS, diese rekombinante DNS enthaltender Mikroorganismus und Verfahren zur Herstellung von L-Aminosäure unter Verwendung dieses Mikroorganismus
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
ATE263251T1 (de) Rekombinanter bakulovirus und sein verwendung zur herstellung monoklonaler antikörper
SG70560A1 (en) Neurotrophin-3 a novel neurotrophic factor related to nerve growth factor and brain derived neurotrophic factor
DE69013811D1 (de) Verfahren zur Herstellung von antiviralem Protein unter Benützung von E.coli-Transformant, das Gen, das für dieses Protein kodiert und E.coli-Vektor benützt in diesem Verfahren.
DE3776857D1 (de) Aequoringen-varianten und verfahren zur herstellung von entsprechenden aequorinproteinen.
DE69513186D1 (de) Photokatalysator, methode zur dessen herstellung, und erzeugung von wasserstoff unter verwendung des photokatalysators
DE59101580D1 (de) Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.
ATE457354T1 (de) Für ein a. thaliana protein kodierende dna- sequenz mit delta-5,7-sterol-delta-7- reduktaseaktivität, das protein, verfahren zur herstellung, transformierte hefe-stämme und verwendungen
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
DE69504620D1 (de) Monoklonaler Antikörper gegen menschliches Glicentin, Hybridoma zur Herstellung dieses Antikörpers und Testverfahren für menschliches Glicentin unter Verwendung dieses Antikörpers
DE69728897D1 (de) Saeugetierchemokine
ATE127478T1 (de) Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung.
DE3750240D1 (de) Gen, das ein Insektizid-Protein kodiert, und Herstellung des Proteins durch Verwendung dieses Gens.
DE69530647D1 (de) Für biosynthetische Insulinvorstufen kodierende DNA-Sequenzen und Verfahren zur Herstellung von Insulin
DE3678552D1 (de) Verfahren zur herstellung von proteinen unter verwendung von transformierten milchsaeurebakterien.
DE3786870D1 (de) Methode zur herstellung von proteinen.
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.